October 16th 2024
Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.
National Recovery Month is a Time for Action
September 27th 2021With the headlines focused on COVID-19, many may have forgotten about the escalating epidemic of substance use disorder. National Recovery Month is a time to bring this issue back to the top of the agenda, raise awareness, and drive action, writes Richard Pops, CEO of Alkermes.
Moving Beyond Traditional Approaches to Alzheimer’s Disease
June 8th 2021The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
The Cultural Deficit in the Pharma Industry in the Era of COVID-19
September 10th 2020Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?